Trial reportDiabetologia2023
Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Trial report in Diabetologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03945656 (A Trial Investigating the Hypoglycaemic Response to Overdosing of NNC0148-0287 C), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Trial Investigating the Hypoglycaemic Response to Overdosing of NNC0148-0287 C (Insulin 287) in Subjects With Type 2 Diabetes
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once-Weekly Basal Insulin Icodec.Diabetes, obesity & metabolism · 2026Article
- Electronic health record-derived machine learning model for hypoglycemia risk prediction in type 2 diabetes mellitus patients: development and validation.BMC endocrine disorders · 2026Article
- Review
- Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus.Reviews in endocrine & metabolic disorders · 2025Review
- The rise of weekly insulins: addressing the challenges of type 2 diabetes care in Brazil.Diabetology & metabolic syndrome · 2025Review
- Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes.Diabetologia · 2024Review
- Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Counseling for Insulin Icodec: A Proposed Practitioner's Guide.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2024Article
- The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.Endocrine reviews · 2024Review
- The 2022 American Diabetes Association Meeting.Journal of diabetes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisThis study compared the frequency of hypoglycaemia, time to hypoglycaemia and recovery from hypoglycaemia after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100. Furthermore, the symptomatic and counterregulatory responses to hypoglycaemia were compared between icodec and glargine U100 treatment.
methodsIn a randomised, single-centre (Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria), open-label, two-period crossover trial, individuals with type 2 diabetes (age 18-72 years, BMI 18.5-37.9 kg/m
resultsHypoglycaemia induction was initiated in 43 and 42 participants after double dose of icodec and glargine U100, respectively, and in 38 and 40 participants after triple doses, respectively. Clinically significant hypoglycaemia, defined as PG CONCLUSIONS/
interpretationDouble or triple doses of once-weekly icodec lead to a similar risk of hypoglycaemia compared with double or triple doses of once-daily glargine U100. During hypoglycaemia, comparable symptomatic and moderately greater endocrine responses are elicited by icodec vs glargine U100.
trial registrationClinicalTrials.gov NCT03945656.
fundingThis study was funded by Novo Nordisk A/S.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.